Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 47
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Am J Trop Med Hyg ; 107(2): 388-392, 2022 08 17.
Article de Anglais | MEDLINE | ID: mdl-35895408

RÉSUMÉ

PXVX0200 is an oral cholera vaccine that is approved for use by the U.S. Food and Drug Administration and European Medicines Agency under the tradename Vaxchora. The vaccine is supplied as two packets, one containing buffer component and the other the active component, that are mixed with water and ingested. The aim of this study was to develop vaccine preparation methods that are appropriate for administering PXVX0200 to children. Developing oral liquid medication for children has unique challenges, including administration volume and palatability. These challenges were addressed by preparing PXVX0200 in different volumes and testing the potency of the vaccine in the presence of sweeteners, flavorings, and food and drinks. Vaccine potency, defined as colony-forming units/dose, was used to determine the compatibility of PXVX0200 with different vaccine preparation methods. We found that the reconstitution volume can be reduced from 100 to 50 mL to accommodate children aged 2 to 6 years and to 10 mL for children aged 6 months to 2 years, as long as the buffer concentration is the same as for the approved (100 mL) dose. Sucrose or stevia sweeteners may also be added without affecting the vaccine potency. Reconstitution in juices or foods was challenging because of effervescence caused by bicarbonate in the buffer component. An alternate preparation method was developed for reconstitution in baby formula. Vaccine preparation methods to make PXVX0200 appropriate for pediatric administration will facilitate administration of the vaccine to improve compliance and protect children from cholera infection while traveling.


Sujet(s)
Vaccins anticholériques , Vibrio cholerae , Humains , Enfant , Administration par voie orale , Anticorps antibactériens , Préparation pour nourrissons
2.
Sci Rep ; 11(1): 13188, 2021 06 23.
Article de Anglais | MEDLINE | ID: mdl-34162914

RÉSUMÉ

CVD 103-HgR live, attenuated oral cholera vaccine strain is indicated for single dose immunization against Vibrio cholerae, the causative agent for cholera. The vaccine packets containing buffer powder and lyophilized CVD 103-HgR are reconstituted in water and consumed. Studies were performed to explore the viability of CVD 103-HgR in drinking waters from common sources. CVD 103-HgR vaccine was reconstituted in bottled and tap waters from the United States and Europe, and viability was measured via colony forming units assay. Chemical analysis of select water samples was used to identify chemicals that have a negative effect on CVD 103-HgR viability. CVD 103-HgR titers were stable in all bottled waters tested, including purified bottled water, bottled spring water, and sparkling waters. However, tap water from certain cities in the US and Europe affected viability and are not compatible with vaccine. Water chemistry revealed that these tap waters contained copper, likely leached from copper plumbing. These studies give high confidence in the stability of CVD 103-HgR reconstituted in a variety of bottled waters. Waters containing copper, including tap water, should not be used to reconstitute CVD 103-HgR strain oral vaccine due to the common use of copper plumbing.


Sujet(s)
Vaccins anticholériques , Eau de boisson/microbiologie , Vibrio cholerae/physiologie , Charge bactérienne , Chlore/analyse , Cuivre/analyse , Eau de boisson/composition chimique , Europe , Fluorures/analyse , Hydrocarbures halogénés/analyse , Génie sanitaire , Trihalogénométhanes/analyse , États-Unis , Vaccins atténués , Vibrio cholerae/effets des médicaments et des substances chimiques , Vibrio cholerae/isolement et purification , Purification de l'eau
3.
Am J Trop Med Hyg ; 104(4): 1232-1240, 2021 03 01.
Article de Anglais | MEDLINE | ID: mdl-33646977

RÉSUMÉ

Vaccination is a well-established means for prevention and spread of disease in people traveling abroad. Although vaccines to diseases such as cholera are recommended by world health agencies, they are seldom required even when traveling to endemic regions. Consequences of noncompliance can affect traveler's health and spread diseases to new regions, as occurred in Haiti in 2010 when United Nations peacekeepers from Nepal, where a cholera outbreak was underway, introduced the disease to the region. Steps to increase vaccine recommendation compliance should therefore be an integral part of vaccine development. PXVX0200 contains Center for Vaccine Development 103-HgR live, attenuated recombinant Vibrio cholerae vaccine strain, and is indicated for single-dose immunization against the bacteria that causes cholera. It is supplied as one buffer and one active component packet to be mixed into water and ingested. Administration instructions are designed to be "user friendly" with flexibility for self-administration, thus promoting compliance. Studies to support self-administration were conducted to cover stability of the vaccine outside of normal storage conditions, potency in case of misadministration, and disposal procedures to minimize environmental impact. The principal findings showed that the stability of vaccine was maintained under conditions allowing for transport times and temperature conditions as well as when misadministration errors were made. Finally, the vaccine was effectively neutralized with hot water and soap to prevent bacterial environmental contamination in the event of an accidental spill. The conclusion is that PXVX0200 oral vaccine is stable, easy to formulate and dispose of, and is amenable to self-administration.


Sujet(s)
Vaccins anticholériques/administration et posologie , Choléra/prévention et contrôle , Vaccination/méthodes , Efficacité du vaccin , Vibrio cholerae/immunologie , Administration par voie orale , Anticorps antibactériens/sang , Haïti , Services de soins à domicile , Humains , Népal , Température
4.
Sci Rep ; 8(1): 1676, 2018 01 26.
Article de Anglais | MEDLINE | ID: mdl-29374211

RÉSUMÉ

Type III solar radio bursts are the Sun's most intense and frequent nonthermal radio emissions. They involve two critical problems in astrophysics, plasma physics, and space physics: how collective processes produce nonthermal radiation and how magnetic reconnection occurs and changes magnetic energy into kinetic energy. Here magnetic reconnection events are identified definitively in Solar Dynamics Observatory UV-EUV data, with strong upward and downward pairs of jets, current sheets, and cusp-like geometries on top of time-varying magnetic loops, and strong outflows along pairs of open magnetic field lines. Type III bursts imaged by the Murchison Widefield Array and detected by the Learmonth radiospectrograph and STEREO B spacecraft are demonstrated to be in very good temporal and spatial coincidence with specific reconnection events and with bursts of X-rays detected by the RHESSI spacecraft. The reconnection sites are low, near heights of 5-10 Mm. These images and event timings provide the long-desired direct evidence that semi-relativistic electrons energized in magnetic reconnection regions produce type III radio bursts. Not all the observed reconnection events produce X-ray events or coronal or interplanetary type III bursts; thus different special conditions exist for electrons leaving reconnection regions to produce observable radio, EUV, UV, and X-ray bursts.

5.
Mucosal Immunol ; 7(4): 857-68, 2014 Jul.
Article de Anglais | MEDLINE | ID: mdl-24280938

RÉSUMÉ

Phagocytes not only coordinate acute inflammation and host defense at mucosal sites, but also contribute to tissue damage. Respiratory infection causes a globally significant disease burden and frequently progresses to acute respiratory distress syndrome, a devastating inflammatory condition characterized by neutrophil recruitment and accumulation of protein-rich edema fluid causing impaired lung function. We hypothesized that targeting the intracellular protein myeloid cell leukemia 1 (Mcl-1) by a cyclin-dependent kinase inhibitor (AT7519) or a flavone (wogonin) would accelerate neutrophil apoptosis and resolution of established inflammation, but without detriment to bacterial clearance. Mcl-1 loss induced human neutrophil apoptosis, but did not induce macrophage apoptosis nor impair phagocytosis of apoptotic neutrophils. Neutrophil-dominant inflammation was modelled in mice by either endotoxin or bacteria (Escherichia coli). Downregulating inflammatory cell Mcl-1 had anti-inflammatory, pro-resolution effects, shortening the resolution interval (Ri) from 19 to 7 h and improved organ dysfunction with enhanced alveolar-capillary barrier integrity. Conversely, attenuating drug-induced Mcl-1 downregulation inhibited neutrophil apoptosis and delayed resolution of endotoxin-mediated lung inflammation. Importantly, manipulating lung inflammatory cell Mcl-1 also accelerated resolution of bacterial infection (Ri; 50 to 16 h) concurrent with enhanced bacterial clearance. Therefore, manipulating inflammatory cell Mcl-1 accelerates inflammation resolution without detriment to host defense against bacteria, and represents a target for treating infection-associated inflammation.


Sujet(s)
Poumon/immunologie , Poumon/métabolisme , Protéine Mcl-1/métabolisme , Animaux , Apoptose/effets des médicaments et des substances chimiques , Apoptose/immunologie , Caspases/métabolisme , Modèles animaux de maladie humaine , Femelle , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Humains , Poumon/microbiologie , Poumon/anatomopathologie , Macrophages/effets des médicaments et des substances chimiques , Macrophages/immunologie , Macrophages/métabolisme , Souris , Protéine Mcl-1/génétique , Infiltration par les neutrophiles/immunologie , Granulocytes neutrophiles/effets des médicaments et des substances chimiques , Granulocytes neutrophiles/immunologie , Granulocytes neutrophiles/métabolisme , Pipéridines/pharmacologie , Pneumopathie infectieuse/génétique , Pneumopathie infectieuse/immunologie , Pneumopathie infectieuse/métabolisme , Pneumopathie infectieuse/microbiologie , Pneumopathie infectieuse/anatomopathologie , Pyrazoles/pharmacologie
6.
Cell Death Differ ; 19(12): 1950-61, 2012 Dec.
Article de Anglais | MEDLINE | ID: mdl-22743999

RÉSUMÉ

Terminally differentiated neutrophils are short-lived but the key effector cells of the innate immune response, and have a prominent role in the pathogenesis and propagation of many inflammatory diseases. Delayed apoptosis, which is responsible for their extended longevity, is critically dependent on a balance of intracellular survival versus pro-apoptotic proteins. Here, we elucidate the mechanism by which the cyclin-dependent kinase (CDK) inhibitor drugs such as R-roscovitine and DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole) mediate neutrophil apoptosis. We demonstrate (by a combination of microarray, confocal microscopy, apoptosis assays and western blotting) that the phosphorylation of RNA polymerase II by CDKs 7 and 9 is inhibited by R-roscovitine and that specific effects on neutrophil transcriptional capacity are responsible for neutrophil apoptosis. Finally, we show that specific CDK7 and 9 inhibition with DRB drives resolution of neutrophil-dominant inflammation. Thus, we highlight a novel mechanism that controls both primary human neutrophil transcription and apoptosis that could be targeted by selective CDK inhibitor drugs to resolve established inflammation.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Kinase-9 cycline-dépendante/métabolisme , Kinases cyclines-dépendantes/métabolisme , Granulocytes neutrophiles/enzymologie , Inhibiteurs de protéines kinases/pharmacologie , Kinase-9 cycline-dépendante/antagonistes et inhibiteurs , Kinases cyclines-dépendantes/antagonistes et inhibiteurs , Dichlororibofuranosylbenzimidazole/pharmacologie , Cellules HL-60 , Cellules HepG2 , Humains , Inflammation/métabolisme , Inflammation/anatomopathologie , Granulocytes neutrophiles/effets des médicaments et des substances chimiques , Phosphorylation , Purines/pharmacologie , RNA polymerase II/métabolisme , Roscovitine , Transcription génétique , Kinase activatrice des CDK
7.
Eur Respir J ; 39(3): 546-57, 2012 Mar.
Article de Anglais | MEDLINE | ID: mdl-21828028

RÉSUMÉ

Lung exposure to metal oxide nanoparticles (NPs) comprising soluble metal haptens may produce T-helper cell type 1 (Th1)- and Th17-associated delayed-type hypersensitivity (DTH) responses and pulmonary alveolar proteinosis (PAP). In order to study this, haptenic metal oxide NPs (NiO, Co(3)O(4), Cr(2)O(3) and CuO) were instilled into the lungs of female Wistar rats, and the immunoinflammatory responses were assessed at 24 h and 4 weeks post-instillation. Primary culture of alveolar macrophages from Wistar rats was used to evaluate the effect of the NPs on the ability to clear surfactant. NiO NPs induced chronic interstitial inflammation and pro-inflammatory Th1 and Th17 immune responses characterised by increases in the cytokines monocyte chemotactic protein (MCP)-1/CCL2, interleukin (IL)-12 p40, interferon-γ and IL-17A, whilst similar pathological responses induced by Co(3)O(4) NPs were associated with increases in MCP-1/CCL2 and IL-12 p40. However, neither Cr(2)O(3) nor CuO NPs elicited immunoinflammatory reactions. PAP was induced by both NiO and Co(3)O(4) NPs during the chronic phase. PAP was associated with over-production of surfactant by proliferation of type II cells and impaired clearance of surfactant by macrophages. These findings have implications for the risk management of occupational NP exposure and provide evidence that haptenic metal oxide NPs can induce chronic progressive lung immune responses via a DTH-like mechanism.


Sujet(s)
Cobalt/toxicité , Nanoparticules métalliques/effets indésirables , Nickel/toxicité , Oxydes/toxicité , Protéinose alvéolaire pulmonaire/induit chimiquement , Animaux , Liquide de lavage bronchoalvéolaire/cytologie , Prolifération cellulaire , Cellules cultivées/immunologie , Composés du chrome/toxicité , Cuivre/toxicité , Cytokines/biosynthèse , Cytokines/immunologie , Femelle , Réaction à corps étranger/induit chimiquement , Réaction à corps étranger/immunologie , Hypersensibilité retardée/induit chimiquement , Hypersensibilité retardée/immunologie , Poumon/effets des médicaments et des substances chimiques , Poumon/métabolisme , Poumon/anatomopathologie , Macrophages alvéolaires/effets des médicaments et des substances chimiques , Macrophages alvéolaires/immunologie , Macrophages alvéolaires/métabolisme , Nanoparticules métalliques/ultrastructure , Protéinose alvéolaire pulmonaire/immunologie , Surfactants pulmonaires/métabolisme , Rats , Rat Wistar
8.
Br J Pharmacol ; 164(6): 1661-71, 2011 Nov.
Article de Anglais | MEDLINE | ID: mdl-21542833

RÉSUMÉ

BACKGROUND AND PURPOSE: Dissociating anti-inflammatory efficacy from the metabolic side effects of glucocorticoids is an attractive therapeutic goal. 5α-Tetrahydro-corticosterone (5αTHB), produced from corticosterone by 5α-reductases, activates glucocorticoid receptors. This study compares the effects of 5αTHB on inflammation and metabolism in vitro and in vivo. METHODS: Suppression of cytokine release by 5αTHB and corticosterone were studied following LPS activation of mouse bone marrow derived macrophages. In vivo the efficacy of these steroids to dysregulate metabolic homeostasis and modulate immune suppression and the responses to thioglycollate-induced peritonitis in C57BL/6 mice were studied following acute injection (1.5-15 mg) and chronic infusion (50 µg·day(-1) , 14 days). RESULTS: In macrophages, 5αTHB increased secretion of IL-10 similarly to corticosterone (180%, 340%; data are % vehicle, treated with 5αTHB and corticosterone, respectively) and suppressed LPS-induced secretion of TNF-α (21.9%, 74.2%) and IL-6 (16.4%, 69.4%). In mice with thioglycollate-induced peritonitis, both 5αTHB and corticosterone reduced the numbers of neutrophils (58.6%, 49.9%) and inflammatory monocytes (69.5%, 96.4%), and also suppressed MCP-1 (48.7%, 80.9%) and IL-6 (53.5%, 86.7%) in peritoneal exudate. In mice chronically infused with 5αTHB and corticosterone LPS-induced production of TNF-α from whole blood was suppressed to the same degree (63.2%, 37.2%). However, in contrast to corticosterone, 5αTHB did not induce body weight loss, increase blood pressure or induce hyperinsulinaemia. CONCLUSIONS: 5αTHB has anti-inflammatory effects in vitro and in vivo. At doses with equivalent anti-inflammatory efficacy to corticosterone, 5αTHB did not induce metabolic toxicity and thus may be a prototype for a safer anti-inflammatory drug.


Sujet(s)
Anti-inflammatoires/usage thérapeutique , Corticostérone/analogues et dérivés , Péritonite/traitement médicamenteux , Animaux , Anti-inflammatoires/pharmacologie , Cellules cultivées , Corticostérone/pharmacologie , Corticostérone/usage thérapeutique , Cytokines/sang , Cytokines/immunologie , Macrophages/effets des médicaments et des substances chimiques , Macrophages/métabolisme , Mâle , Souris , Souris de lignée C57BL , Monocytes/effets des médicaments et des substances chimiques , Monocytes/immunologie , Granulocytes neutrophiles/effets des médicaments et des substances chimiques , Granulocytes neutrophiles/immunologie , Péritonite/induit chimiquement , Péritonite/immunologie , Thioglycolates
9.
Am J Physiol Lung Cell Mol Physiol ; 299(2): L263-71, 2010 Aug.
Article de Anglais | MEDLINE | ID: mdl-20435687

RÉSUMÉ

Induction of effective inflammation in the lung in response to environmental and microbial stimuli is dependent on cooperative signaling between leukocytes and lung tissue cells. We explored how these inflammatory networks are modulated by diesel exhaust particles (DEP) using cocultures of human monocytes with epithelial cells. Cocultures, or monoculture controls, were treated with DEP in the presence or absence of LPS or flagellin. Production of cytokines was explored by Western blotting and ELISA; cell signaling was analyzed by Western blotting. Here, we show that responses of epithelial cells to DEP are amplified by the presence of monocytes. DEP amplified the responses of cellular cocultures to very low doses of TLR agonists. In addition, in the presence of DEP, the responses induced by LPS or flagellin were less amenable to antagonism by the physiological IL-1 antagonist, IL-1ra. This was paralleled by the uncoupling of IL-1 production and release from monocytes, potentially attributable to an ability of DEP to sequester or degrade extracellular ATP. These data describe a model of inflammation where DEP amplifies responses to low concentrations of microbial agonists and alters the nature of the inflammatory milieu induced by TLR agonists.


Sujet(s)
Inflammation/immunologie , Poumon/immunologie , Emissions des véhicules/toxicité , Adénosine triphosphate/métabolisme , Lignée cellulaire , Techniques de coculture , Cytokines/biosynthèse , Flagelline/pharmacologie , Humains , Antagoniste du récepteur à l'interleukine-1/immunologie , Interleukine-1/physiologie , Interleukine-1 bêta/biosynthèse , Interleukine-8/biosynthèse , Lipopolysaccharides/pharmacologie , Monocytes/immunologie , Muqueuse respiratoire/cytologie , Transduction du signal/physiologie , Récepteurs de type Toll/agonistes
10.
Blood Purif ; 29(2): 210-5, 2010.
Article de Anglais | MEDLINE | ID: mdl-20093829

RÉSUMÉ

Hepatitis C virus (HCV) infection can be cured by standard pegylated interferon (IFN) + ribavirin drug therapy in 30-50% of treatment-naïve genotype 1 HCV patients. Cure rate is defined as a sustained viral response measured 6 months after the end of treatment. Recently, Fujiwara et al. [Hepatol Res 2007;37:701-710], using a double-filtration plasmapheresis (DFPP) technique, showed that simple physical reduction in circulating HCV using a 1-week pretreatment increased the cure rate for treatment-naïve type 1 HCV patients from 50 (controls) to 78% (treated). For previous nonresponders, the cure rate increased from 30 to 71%. This effect occurs even though the DFPP per treatment HCV viral load reduction averaged 26%. In clinical studies discussed here, a lectin affinity plasmapheresis (LAP) device caused an estimated 41% decrease in viral load as previously reported. A more detailed analysis using normalized data to correct for any variations in initial viral load gave an average 29% per treatment viral load reduction in 5 HCV-positive dialysis patients. The latter data indicate that continuous application of LAP could bring HCV viral load to undetectable levels in 4.1 days. Compared to DFPP, the LAP approach has the advantage that no plasma losses are incurred. In addition hemopurification can be carried out for extended periods of time analogous to continuous renal replacement therapy for the treatment of acute kidney failure, making the process much more effective. Calculations based on these data predict that continuous hemopurification would substantially increase the rate of viral load reduction (approx. 14-fold) and therefore increase the cure rate for HCV standard-of-care drug therapies without adding additional drugs and their associated side effects.


Sujet(s)
Antiviraux/usage thérapeutique , Hépatite C chronique/thérapie , Interféron alpha/usage thérapeutique , Lectines liant le mannose/pharmacologie , Modèles biologiques , Lectines végétales/pharmacologie , Plasmaphérèse/méthodes , Polyéthylène glycols/usage thérapeutique , Ribavirine/usage thérapeutique , Détoxication par sorption/méthodes , Virémie/thérapie , Antiviraux/administration et posologie , Essais cliniques comme sujet , Association thérapeutique , Association de médicaments , Hépatite C chronique/complications , Hépatite C chronique/traitement médicamenteux , Humains , Interféron alpha-2 , Interféron alpha/administration et posologie , Défaillance rénale chronique/complications , Défaillance rénale chronique/thérapie , Polyéthylène glycols/administration et posologie , Protéines recombinantes , Dialyse rénale/méthodes , Ribavirine/administration et posologie , Résultat thérapeutique , Charge virale , Virémie/traitement médicamenteux
11.
Blood Purif ; 27(1): 64-9, 2009.
Article de Anglais | MEDLINE | ID: mdl-19169020

RÉSUMÉ

BACKGROUND/AIMS: To test the safety and efficacy of the Aethlon Hemopurifier, a lectin affinity cartridge, in clearing hepatitis C virus (HCV) from the blood of HCV-positive end-stage renal disease patients undergoing dialysis. Viral RNA was measured using real-time quantitative reverse transcriptase polymerase chain reaction. RESULTS: HCV clearance from plasma or blood was measured using either direct capture on immobilized Galanthus nivalis agglutinin (GNA) or using miniature plasmapheresis cartridges containing immobilized GNA. HCV in plasma samples was rapidly cleared by direct affinity capture (t(1/2) = approx. 20 min) and HCV in human blood was cleared using the Hemopurifier (t(1/2) = 2-3 h). Institutional-review-board-sanctioned clinical safety studies were conducted at the Apollo and Fortis Hospitals in India. At Apollo, 4 patients were treated 3 times/week for 2 weeks. HCV captured on the Hemopurifier averaged 8.9 x 10(8) viral copies/cartridge (n = 5), representing approximately 30% of the initial viral body burden. At Fortis, 3 patients treated 3 times/week for 1 week completed the viral load studies. Two patients showed measurable viral load reduction, while the third showed both increases and decreases in viral load. After Hemopurifier treatment, average HCV viral load was reduced by 57%. Surprisingly, average viral load was also 82% lower 7 days after treatment. Control samples also showed a marked transient reduction in HCV viral load as previously reported. CONCLUSION: The Hemopurifier rapidly cleared HCV from blood treated in vitro. In patients, the combination of the Hemopurifier plus dialysis decreased HCV viral load by 57% in 1 week. Moreover, viral load reduction continued up to 7 days after treatment.


Sujet(s)
Hepacivirus/isolement et purification , Défaillance rénale chronique/complications , Défaillance rénale chronique/thérapie , Lectines/usage thérapeutique , Plasmaphérèse/méthodes , Chromatographie d'affinité , Hépatite C/thérapie , Humains , Plasmaphérèse/instrumentation , Réaction de polymérisation en chaîne , ARN viral/sang , Charge virale
12.
Mucosal Immunol ; 1(5): 350-63, 2008 Sep.
Article de Anglais | MEDLINE | ID: mdl-19079199

RÉSUMÉ

The respiratory mucosa is responsible for gas exchange and is therefore, of necessity, exposed to airborne pathogens, allergens, and foreign particles. It has evolved a multi-faceted, physical and immune defense system to ensure that in the majority of instances, potentially injurious invaders are repelled. Inflammation, predominantly mediated by effector cells of the granulocyte lineage including neutrophils and eosinophils, is a form of immune defense. Where inflammation proves unable to remove an inciting stimulus, chronic inflammatory disease may supervene because of the potential for tissue damage conferred by the presence of large numbers of frustrated, activated granulocytes. Successful recovery from inflammatory disease and resolution of inflammation rely on the clearance of these cells. Ideally, they should undergo apoptosis prior to phagocytosis by macrophage, dendritic, or epithelial cells. The outcome of inflammation can have serious sequelae for the integrity of the respiratory mucosa leading to disease. Therapeutic strategies to drive resolution of inflammation may be directed at the induction of granulocyte apoptosis and the enhancement of granulocyte clearance.


Sujet(s)
Apoptose/immunologie , Granulocytes/cytologie , Granulocytes/immunologie , Muqueuse respiratoire/immunologie , Animaux , Fibrose/immunologie , Fibrose/anatomopathologie , Humains , Inflammation/immunologie , Inflammation/anatomopathologie , Phagocytose/immunologie , Muqueuse respiratoire/anatomopathologie
13.
Br J Pharmacol ; 153(4): 623-4, 2008 Feb.
Article de Anglais | MEDLINE | ID: mdl-18084311

RÉSUMÉ

Although sildenafil (Viagra) and other phosphodiesterase V (PDE V) inhibitors are increasingly recognized for their use in the treatment of male erectile dysfunction and perhaps more recently pulmonary artery hypertension, less is known of their potential beneficial effects in other situations. Medeiros et al., in the current issue of the British Journal of Pharmacology, report that sildenafil dramatically reduces alcohol-induced gastric damage in rats. The authors provide convincing evidence that such protection not only occurs via the nitric oxide (NO)/cGMP pathway, but also involves regulation of ATP-sensitive potassium channels. Therefore, in addition to exerting anti-impotence efficacy, PDE V inhibitors may provide significant beneficial effects from mucosal injury induced by alcohol.


Sujet(s)
GMP cyclique/métabolisme , Muqueuse gastrique/effets des médicaments et des substances chimiques , Canaux KATP/métabolisme , Monoxyde d'azote/métabolisme , Hémorragie de l'ulcère gastroduodénal/prévention et contrôle , Inhibiteurs de la phosphodiestérase/pharmacologie , Pipérazines/pharmacologie , Ulcère gastrique/prévention et contrôle , Sulfones/pharmacologie , Animaux , Arginine/métabolisme , Cyclic Nucleotide Phosphodiesterases, Type 5/métabolisme , Modèles animaux de maladie humaine , Éthanol , Muqueuse gastrique/enzymologie , Muqueuse gastrique/métabolisme , Muqueuse gastrique/anatomopathologie , Glutathion/métabolisme , Guanylate cyclase/métabolisme , Hémoglobines/métabolisme , Canaux KATP/effets des médicaments et des substances chimiques , Nitric oxide synthase/métabolisme , Hémorragie de l'ulcère gastroduodénal/étiologie , Hémorragie de l'ulcère gastroduodénal/métabolisme , Hémorragie de l'ulcère gastroduodénal/anatomopathologie , Inhibiteurs de la phosphodiestérase-5 , Inhibiteurs de la phosphodiestérase/usage thérapeutique , Pipérazines/usage thérapeutique , Purines/pharmacologie , Purines/usage thérapeutique , Rats , Transduction du signal/effets des médicaments et des substances chimiques , Citrate de sildénafil , Ulcère gastrique/induit chimiquement , Ulcère gastrique/complications , Ulcère gastrique/métabolisme , Ulcère gastrique/anatomopathologie , Sulfones/usage thérapeutique
14.
Toxicol Appl Pharmacol ; 219(1): 62-71, 2007 Feb 15.
Article de Anglais | MEDLINE | ID: mdl-17239416

RÉSUMÉ

To investigate the role of the vagus nerve in acute inflammatory and cardiorespiratory responses to diesel particulate (DP) in the rat airway, we measured changes in respiration, blood pressure and neutrophils in lungs of urethane anesthetized Wistar rats 6-h post-instillation of DP (500 microg) and studied the effect of mid-cervical vagotomy or atropine (1 mg kg(-1)) pre-treatment. In conscious rats, we investigated DP, with and without atropine pre-treatment. DP increased neutrophil level in BAL (bronchoalveolar lavage) fluid from intact anesthetized rats to 2.5+/-0.7x10(6) cells (n=8), compared with saline instillation (0.3+/-0.1x10(6), n=7; P<0.05). Vagotomy reduced DP neutrophilia to 0.8+/-0.2x10(6) cells (n=8; P<0.05 vs. intact); atropine reduced DP-induced neutrophilia to 0.3+/-0.2x10(6) (n=4; P<0.05). In conscious rats, DP neutrophilia of 8.5+/-1.8x10(6), n=4, was reduced by pre-treatment with atropine to 2.2+/-1.2x10(6) cells, n=3. Hyperventilation occurred 6 h after DP in anesthetized rats with intact vagi, but not in bilaterally vagotomized or atropine pre-treated animals and was abolished by vagotomy (P<0.05, paired test). There were no significant differences in the other variables (mean blood pressure, heart rate and heart rate variability) measured before and 360 min after DP. In conclusion, DP activates a pro-inflammatory vago-vagal reflex which is reduced by atropine. Muscarinic ACh receptors in the rat lung are involved in DP-induced neutrophilia, and hence muscarinic antagonists may reduce airway and/or cardiovascular inflammation evoked by inhaled atmospheric DP in susceptible individuals.


Sujet(s)
Atropine/pharmacologie , Antagonistes muscariniques/pharmacologie , Pneumopathie infectieuse/prévention et contrôle , Vagotomie , Emissions des véhicules/toxicité , Maladie aigüe , Animaux , Pression sanguine/effets des médicaments et des substances chimiques , Liquide de lavage bronchoalvéolaire/cytologie , Interprétation statistique de données , Rythme cardiaque/effets des médicaments et des substances chimiques , Macrophages/anatomopathologie , Macrophages/ultrastructure , Mâle , Granulocytes neutrophiles/anatomopathologie , Granulocytes neutrophiles/ultrastructure , Pneumopathie infectieuse/induit chimiquement , Pneumopathie infectieuse/physiopathologie , Circulation pulmonaire/effets des médicaments et des substances chimiques , Rats , Rat Wistar , Mécanique respiratoire/effets des médicaments et des substances chimiques
15.
Toxicol Lett ; 149(1-3): 255-9, 2004 Apr 01.
Article de Anglais | MEDLINE | ID: mdl-15093271

RÉSUMÉ

Modification of the quartz surface by aluminium salts and metallic iron have been shown to reduce the biological activity of quartz. This study aimed to investigate the ability of water soluble extracts of coal mine dust (CMD), low aluminium clays (hectorite and montmorillonite) and high aluminium clays (attapulgite and kaolin) to inhibit the reactivity of the quartz surface. DQ12 induced significant haemolysis of sheep erythrocytes in vitro and inflammation in vivo as indicated by increases in the total cell numbers, neutrophil cell numbers, MIP-2 protein and albumin content of bronchoalveolar lavage (BAL) fluid. Treatment of DQ12 with CMD extract prevented both haemolysis and inflammation. Extracts of the high aluminium clays (kaolin and attapulgite) prevented inhibition of DQ12 induced haemolysis, and the kaolin extract inhibited quartz driven inflammation. DQ12 induced haemolysis by coal mine dust and kaolin extract could be prevented by pre-treatment of the extracts with a cation chellator. Extracts of the low aluminium clays (montmorillonite and hectorite) did not prevent DQ12 induced haemolysis, although the hectorite extract did prevent inflammation. These results suggest that CMD, and clays both low and rich in aluminium, all contain soluble components (possibly cations) capable of masking the reactivity of the quartz surface.


Sujet(s)
Silicates d'aluminium/toxicité , Charbon , Poussière , Quartz/toxicité , Administration par inhalation , Silicates d'aluminium/composition chimique , Animaux , Liquide de lavage bronchoalvéolaire/composition chimique , Liquide de lavage bronchoalvéolaire/cytologie , Argile , Érythrocytes/effets des médicaments et des substances chimiques , Hémolyse/effets des médicaments et des substances chimiques , Techniques in vitro , Kaolin/composition chimique , Kaolin/toxicité , Composés du magnésium/composition chimique , Composés du magnésium/toxicité , Quartz/composition chimique , Rats , Ovis , Composés du silicium/composition chimique , Composés du silicium/toxicité , Solubilité , Propriétés de surface
16.
Blood Purif ; 21(1): 58-63, 2003.
Article de Anglais | MEDLINE | ID: mdl-12566663

RÉSUMÉ

BACKGROUND: HIV-1 gp120 may play a role in the progression from HIV infection to AIDS. AIMS: We investigated affinity hemodialysis for removing gp120 from cell culture and whole blood. METHODS: Anti-gp120 antibodies covalently coupled to agarose beads were packed into columns or hollow-fiber hemodialysis cartridges. Supernatants from HIV-infected HL2/3 cells or gp120 containing whole blood were pumped over the columns and gp120 measured by ELISA. RESULTS: Anti-gp120 agarose removed approximately 90% of HIV-1 gp120 from HL2/3 cultures in 30-60 min. Capture was antibody-dependent (F105 > IDX 1121 > ABI 13-108). Affinity hemodialysis also efficiently captured gp120 from buffer in a first-order, flow-rate-dependent fashion (t((1/2)) = 13 min at 0.9 ml/min). Clearance was faster than calculated diffusion (t((1/2)) approximately 2.5 h) suggesting significant convective transport. gp120 removal from blood was slower (t((1/2)) = 1.4 h). CONCLUSION: Affinity hemodialysis efficiently clears gp120 from cell culture fluids and blood and may be useful in slowing the progression to AIDS.


Sujet(s)
Infections à VIH/thérapie , Dialyse rénale/méthodes , Sang/virologie , Chromatographie d'affinité , Milieux de culture conditionnés , Protéine d'enveloppe gp120 du VIH/sang , Protéine d'enveloppe gp120 du VIH/isolement et purification , Infections à VIH/sang , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Humains , Cinétique , Dialyse rénale/normes
17.
Ther Apher ; 6(3): 213-20, 2002 Jun.
Article de Anglais | MEDLINE | ID: mdl-12109946

RÉSUMÉ

We tested an affinity hemodialysis technique designed to efficiently remove HIV and toxic viral proteins from blood. Miniature polyethersulfone hollow-fiber dialysis cartridges (200-500 nm pore) were packed with anti-HIV antibodies covalently coupled to agarose beads and sealed inside the cartridge. Cell culture fluids, plasma, or infected blood (7-15 ml) containing HIV-1 were circulated over the cartridge at 0.7-10 ml/min and the rate of removal of HIV measured by PCR and p24 ELISA. The technique removed up to 98% of HIV-1 particles from cell culture supernatants. Affinity hemodialysis also efficiently captured cultured HIV from human blood plasma (90%) and native HIV from infected blood (83% to 100%). Viral capture followed first-order kinetics (t(1/2) = 2.8 h). Variations in antibody type, matrix linkage (protein G versus direct coupling), bead pore size, and temperature of operation (25-37 degrees C) had only small effects. Although some binding was nonspecific, direct binding to the immobilized antibodies appeared to be the predominant mechanism.


Sujet(s)
Sang/virologie , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/isolement et purification , Plasma sanguin/virologie , Dialyse rénale/méthodes , Protéines virales/isolement et purification , Maladies virales/prévention et contrôle , Techniques de culture cellulaire , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/physiologie , Humains , ARN viral/analyse , Dialyse rénale/instrumentation , Réplication virale
18.
Toxicol Appl Pharmacol ; 176(1): 10-7, 2001 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-11578144

RÉSUMÉ

In 1997, an IARC Working Group classified quartz (crystalline silica) as a Group 1 lung carcinogen, but only in some industries, i.e., the quartz hazard is a variable entity. The reactivity of the quartz surface may underlie its ability to cause inflammation, and treatments that ameliorate this reactivity will reduce the quartz hazard. In this study we treated quartz (Q) with aluminium lactate (AL), a procedure that is reported to decrease the quartz hazard, and explored the effect this had on the highly reactive quartz surface and on proinflammatory events in rat lungs. Aluminium lactate-treated quartz showed a reduced surface reactivity as measured by electron spin resonance and the hemolysis assay. Eighteen hours after instillation of Q into the rat lung, there was massive inflammation as indicated by the number of neutrophils in the bronchoalveolar lavage (BAL). In addition, Q induced an increase in BAL macrophage inflammatory protein-2 (MIP-2) while ALQ had no significant effect compared to control. Epithelial damage, as indicated by BAL protein and gamma glutamyl transpeptidase, also increased with Q but not with ALQ. Furthermore, Q induced an increase in MIP-2 mRNA by BAL cells while ALQ had no effect compared to controls. There was an increase in nuclear binding of the transcription nuclear factor kappaB (NF-kappaB) in the Q-exposed BAL cells and again no effect on nuclear NF-kappaB binding in BAL cells from ALQ-exposed rats. In conclusion, treatment of the quartz surface with aluminium lactate reduced the reactivity of the particles both in terms of hydroxyl radical generation and in terms of the induction of molecular signaling events leading to inflammation.


Sujet(s)
Composés de l'aluminium/composition chimique , Chimiokines/génétique , Inflammation/induit chimiquement , Lactates/composition chimique , Facteur de transcription NF-kappa B/métabolisme , Quartz/composition chimique , Quartz/pharmacologie , Animaux , Liquide de lavage bronchoalvéolaire/cytologie , Numération cellulaire , Chimiokine CXCL2 , Chimiokines/analyse , Cristallisation , Expression des gènes/effets des médicaments et des substances chimiques , Hémolyse , Humains , Radical hydroxyle/métabolisme , Numération des leucocytes , Poumon/effets des médicaments et des substances chimiques , Mâle , Microscopie électronique à balayage , Granulocytes neutrophiles , Quartz/toxicité , ARN messager/analyse , Rats , Rat Wistar , Propriétés de surface , gamma-Glutamyltransferase/métabolisme
19.
J Environ Pathol Toxicol Oncol ; 20 Suppl 1: 109-18, 2001.
Article de Anglais | MEDLINE | ID: mdl-11570668

RÉSUMÉ

Modification of the quartz surface during the history of the particle is a powerful idea in understanding the variability of the quartz hazard. Interactions between quartz and other minerals are likely to occur in sediments, during industrial processing, or in matrix-bound quartz. We discuss new evidence regarding the basis of changes in the quartz surface that relate to changes in its ability to cause inflammation. Different samples of quartz were subjected to various biological assays. Endpoints included instillation of quartz into the tracheobronchial tree and measurement of PMN numbers in bronchoalveolar lavage (BAL) and in lung tissue, levels of the chemokine MIP-2 in BAL, and nuclear translocation of the transcription factor NF-kappaB in BAL cells. In vitro biological assays included cytotoxicity to epithelial cells, hemolytic activity, and radical activity of the particle surface as measured by electron spin resonance. Treatment of quartz with aluminium lactate impaired its ability to cause PMN recruitment, chemokine release, and NF-kappaB nuclear translocation in BAL. Workplace quartzes had no proinflammatory activity, which correlated with their ability to cause hemolysis but not their electron spin resonance (ESR) activity. Quartz in a matrix with coalmine dust or fly-ash showed different effects. In fly-ash, the toxicity was masked, but coalmine dusts were more toxic to epithelial cells than pure quartz in vitro; however, after instillation, the long-term inflammation was not related to the in vitro activity. Amelioration of quartz surface activity can occur in workplace samples of quartz and quartz samples whose surface is protected, to the extent that they have very little inflammogenic activity and display an inability to activate key subcellular pathways that lead to inflammation. Quartz from a workplace whose surface has been affected, or in a matrix such as coalmine dust or fly-ash, can have its toxicity modulated. These effects are due to minerals and organic compounds that can both decrease (e.g., aluminium salts) or enhance (e.g., coalmine dust matrix) biological activity and thus may contribute to toxicity in a complex way that is not easily predicted. Iron is a good example. There are reports that it can enhance quartz toxicity, or it may have little role to play in its toxicity, as shown here for almost pure quartz particles. A broad program of further research is needed before we have a sound understanding of the mechanisms of quartz toxicity.


Sujet(s)
Polluants atmosphériques d'origine professionnelle/toxicité , Inflammation/métabolisme , Quartz/toxicité , Polluants atmosphériques d'origine professionnelle/composition chimique , Liquide de lavage bronchoalvéolaire/immunologie , Carbone/composition chimique , Carbone/toxicité , Cendre de charbon , Poussière , Humains , Matière particulaire , Quartz/composition chimique , Silice/composition chimique , Silice/toxicité , Propriétés de surface
20.
Toxicol Appl Pharmacol ; 166(2): 101-10, 2000 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-10896851

RÉSUMÉ

Exposure to particulate air pollution (PM(10)) is associated with exacerbations of respiratory diseases and increased cardiopulmonary mortality. PM(10) induces lung inflammation in rats, which has been attributed to many factors, including the ultrafine components of PM(10), endotoxins, and transition metals. In this study, we investigated in alveolar epithelial (A549) cells whether PM(10) could activate nuclear factor-kappa B (NF-kappaB), a transcription factor stimulated in response to many proinflammatory agents. Our results show that PM(10) samples from various sites within the United Kingdom cause nuclear translocation, DNA-binding, and transcriptional activation of NF-kappaB in A549 cells. Furthermore, increased NF-kappaB activity was observed in the absence of IkappaB degradation. To evaluate the role of iron, A549 cells were exposed to PM(10) previously treated with phosphate-buffered saline (PBS), deferoxamine mesylate, or deferoxamine plus ferrozine. PBS-treated and, to a lesser extent, deferoxamine-treated PM(10) were able to activate NF-kappaB, whereas this response was completely abrogated in cells exposed to PM(10) treated with both deferoxamine and ferrozine. Moreover, we studied the effects of soluble components of PM(10) on NF-kappaB activation by exposing alveolar epithelial cells to soluble fractions from PM(10) treated with PBS or the metal chelators. We found that, compared with fractions from PBS-treated PM(10) which activated NF-kappaB, fractions from PM(10) treated with deferoxamine and ferrozine did not stimulate NF-kappaB activity above background levels. Coincubation of polymixin B, an endotoxin-binding compound, and PM(10) did not inhibit NF-kappaB. In summary, PM(10) activates NF-kappaB in A549 cells by an iron-mediated mechanism in the absence of IkappaB degradation.


Sujet(s)
Polluants atmosphériques/pharmacologie , Protéines I-kappa B/métabolisme , Fer/physiologie , Facteur de transcription NF-kappa B/métabolisme , Alvéoles pulmonaires/métabolisme , Adénocarcinome/métabolisme , Noyau de la cellule/métabolisme , ADN/métabolisme , Protéines de liaison à l'ADN/métabolisme , Déferoxamine/pharmacologie , Interactions médicamenteuses , Ferrozine/pharmacologie , Humains , Tumeurs du poumon/métabolisme , Facteur de transcription NF-kappa B/génétique , Taille de particule , Polymyxine B/pharmacologie , Alvéoles pulmonaires/cytologie , Alvéoles pulmonaires/effets des médicaments et des substances chimiques , Cellules cancéreuses en culture
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE